Bonk (NASDAQ:BNKK – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.
Separately, Weiss Ratings lowered shares of Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bonk presently has a consensus rating of “Sell”.
View Our Latest Report on BNKK
Bonk Stock Up 9.7%
Bonk (NASDAQ:BNKK – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $0.79 million for the quarter. Bonk had a negative net margin of 838.37% and a negative return on equity of 148.62%.
Insider Activity
In other Bonk news, Director Mitchell Austin Rudy acquired 31,055 shares of Bonk stock in a transaction that occurred on Thursday, April 9th. The stock was acquired at an average price of $2.82 per share, with a total value of $87,575.10. Following the purchase, the director owned 44,198 shares in the company, valued at approximately $124,638.36. This trade represents a 236.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 51.60% of the company’s stock.
Institutional Investors Weigh In On Bonk
Several institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp acquired a new stake in shares of Bonk in the 4th quarter valued at $33,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Bonk in the 4th quarter valued at $37,000. Jane Street Group LLC acquired a new stake in shares of Bonk in the 4th quarter valued at $96,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Bonk in the 4th quarter valued at $128,000. Institutional investors and hedge funds own 12.55% of the company’s stock.
Bonk Company Profile
Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.
Featured Stories
- Five stocks we like better than Bonk
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Bonk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bonk and related companies with MarketBeat.com's FREE daily email newsletter.
